Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest update is out from Zai Lab Ltd ( (HK:9688) ).
Zai Lab Ltd announced the grant of 9,800 Restricted Share Units to two employees under its 2024 Equity Incentive Plan. This initiative aims to recognize and reward the employees’ contributions and incentivize their continued efforts towards the company’s success. The grants, which have no performance targets or clawback mechanisms, are seen as market competitive and aligned with the company’s practices, potentially enhancing employee retention and motivation.
The most recent analyst rating on (HK:9688) stock is a Buy with a HK$24.34 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Ltd is a biopharmaceutical company incorporated in the Cayman Islands, specializing in the development and commercialization of innovative therapies. The company focuses on addressing unmet medical needs in the fields of oncology, autoimmune disorders, and infectious diseases.
Average Trading Volume: 9,672,544
Technical Sentiment Signal: Hold
Current Market Cap: HK$24.55B
See more data about 9688 stock on TipRanks’ Stock Analysis page.